X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs877399-   
Low Rs424288-   
Sales per share (Unadj.) Rs223.4118.6-  
Earnings per share (Unadj.) Rs31.1-29.9-  
Cash flow per share (Unadj.) Rs40.3-24.8-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.593.1-  
Shares outstanding (eoy) m33.07168.78-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.9 100.6%   
Avg P/E ratio x20.9-11.5 -182.3%  
P/CF ratio (eoy) x16.1-13.9 -116.5%  
Price / Book Value ratio x3.03.7 80.4%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50457,925 37.1%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m1,1283,636 31.0%   
Avg. sales/employee Rs ThNM4,663.4-  
Avg. wages/employee Rs ThNM846.8-  
Avg. net profit/employee Rs ThNM-1,175.1-  
INCOME DATA
Net Sales Rs m7,38920,020 36.9%  
Other income Rs m167140 119.2%   
Total revenues Rs m7,55620,160 37.5%   
Gross profit Rs m1,793-3,469 -51.7%  
Depreciation Rs m304864 35.2%   
Interest Rs m366542 67.5%   
Profit before tax Rs m1,290-4,736 -27.2%   
Minority Interest Rs m46-13 -350.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309296 104.3%   
Profit after tax Rs m1,027-5,045 -20.4%  
Gross profit margin %24.3-17.3 -140.1%  
Effective tax rate %23.9-6.2 -383.0%   
Net profit margin %13.9-25.2 -55.2%  
BALANCE SHEET DATA
Current assets Rs m3,68114,663 25.1%   
Current liabilities Rs m3,1238,250 37.9%   
Net working cap to sales %7.632.0 23.6%  
Current ratio x1.21.8 66.3%  
Inventory Days Days89111 80.7%  
Debtors Days Days59124 47.3%  
Net fixed assets Rs m7,6858,547 89.9%   
Share capital Rs m33193 355.8%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,25915,714 46.2%   
Long term debt Rs m9555,522 17.3%   
Total assets Rs m11,95729,684 40.3%  
Interest coverage x4.5-7.7 -58.5%   
Debt to equity ratio x0.10.4 37.4%  
Sales to assets ratio x0.60.7 91.6%   
Return on assets %11.7-15.2 -76.8%  
Return on equity %14.2-32.1 -44.1%  
Return on capital %20.7-19.8 -104.6%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,4401,709 84.3%  
From Investments Rs m-1,089-525 207.6%  
From Financial Activity Rs m-3535,012 -7.0%  
Net Cashflow Rs m-16,196 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.5 Rs / ZAR

Compare NATCO PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  CADILA HEALTHCARE  GLENMARK PHARMA  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS